Addendum. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2021. Diabetes Care 2021;44(Suppl. 1):S15–S33

Section 2, Classification and Diagnosis of Diabetes, of the Standards of Medical Care in Diabetes-2021 has been annotated to include evidence from a trial on anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes that was reported in 2019, with an extension of the trial reported in 2021.